|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||83.30 - 85.18|
|52-week range||83.30 - 85.18|
|Beta (3Y monthly)||0.94|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
If you own shares in Camurus AB (publ) (STO:CAMX) then it's worth thinking about how it contributes to the volatility...
LUND, Sweden , Nov. 28, 2018 /PRNewswire/ -- Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company's lead products Buvidal® Weekly and Buvidal® Monthly ...
- Buvidal® is the first long-acting medicine approved in the EU for the treatment of opioid dependence in adults and adolescents LUND, Sweden , Nov. 22, 2018 /PRNewswire/ -- Camurus announced today that ...